Phase II Study of Clofarabine in Pediatric Acute Lymphoblastic Leukemia (ALL)
Public ClinicalTrials.gov record NCT00042341. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Open Label Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute lymphoblastic leukemia (ALL) who have had at least 2 prior treatment regimens. The purpose of this study is to determine whether Clofarabine is safe and effective in the treatment of Acute Lymphoblastic Leukemia (ALL.)
Study identification
- NCT ID
- NCT00042341
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 60 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- Up to 21 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2002 (Type not available)
- Primary completion
- Not listed
- Completion
- Jan 2006 (Actual)
- Last update posted
- May 27, 2022
2002 – 2006
United States locations
- U.S. sites
- 14
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Children's Hospital | Los Angeles | California | 90027 | — |
| Children's Hospital | Orange County | California | — | — |
| Children's Hospital | San Diego | California | — | — |
| Children's Hospital | Denver | Colorado | 80218 | — |
| Children's Memorial Hospital | Chicago | Illinois | 60614 | — |
| Johns Hopkins Children's Center | Baltimore | Maryland | — | — |
| Children's Hospital | St Louis | Missouri | — | — |
| Memorial Sloan-Kettering | New York | New York | — | — |
| Children's Hospital | Philadelphia | Pennsylvania | — | — |
| Children's Hospital | Pittsburgh | Pennsylvania | 15213 | — |
| St. Jude Children's Research Hospital | Memphis | Tennessee | — | — |
| Cook's Children's Medical Center | Fort Worth | Texas | 76104 | — |
| Texas Children's Cancer Center | Houston | Texas | — | — |
| The University of Texas M.D. Anderson Cancer Center | Houston | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00042341, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 27, 2022 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00042341 live on ClinicalTrials.gov.